http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2015002170-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbcba9e47d2bb2212a4c38a0000079aa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4353 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate | 2015-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fd84dee2b65c9c222ec5ec40f86a893 |
| publicationDate | 2016-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2015002170-A |
| titleOfInvention | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION. |
| abstract | New pharmaceutical compositions for the treatment of patients with hypertension have been developed in the present invention, using as active principles the blocker of type 1 angiotensin II second-generation receptors Eprosartan combined with the third-generation antagonist calcium Lercanidipine and the hydrochlorothiazide diuretic. These assets, Eprosartan, Lercanidipine, and Hydrochlorothiazide as monopharmaceuticals, have been shown to have greater efficacy and lower adverse effects and greater tolerance, than other commercially available hypertensives. The combinations have been developed in the form of immediate-release and prolonged-release tablets, as well as powders for a suspension, the latter composition that is useful for certain states of patients in which their physical state does not allow the ingestion of tablets or capsules and for cases where immediate bioavailability is required an intravenous injectable presentation has been developed. |
| priorityDate | 2015-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.